4-7-2013 — /europawire.eu/ — Lemminkäinen and Varma Mutual Pension Insurance Company have agreed upon building a commercial centre in Tampere. The Partola Commercial Centre is a joint development project of Lemminkäinen and Varma in which Lemminkäinen acts as both the project developer and main contractor. The construction work has already begun, and it is scheduled for completion in July 2014. The contract value is approximately EUR 13 million.
The Partola Commercial Centre will have 11,000 square metres of net floor space and will be built on a plot owned by Varma. The leases for the new commercial centre have already been signed, and its occupancy rate is 100%.
“The Partola Commercial Centre is a good continuation to the cooperation between us and Varma,” says Janne Salonen, Project Development Manager at Lemminkäinen.
LEMMINKÄINEN CORPORATION
Corporate Communications
ADDITIONAL INFORMATION:
Lemminkäinen Corporation
Janne Salonen, Project Development Manager
Building Construction business segment
Tel. +358 2071 57123
janne.salonen@lemminkainen.com
Varma Mutual Pension Insurance Company
Tuomas Vaarasalo, Construction Manager
Tel. +358 10 244 6698
tuomas.vaarasalo@varma.fi
DISTRIBUTION:
NASDAQ OMX Helsinki
Key media
www.lemminkainen.com
Lemminkäinen Group operates in all areas of the construction sector. The Group’s business segments are building construction, infrastructure construction, technical building services and international operations. Net sales in 2012 were about EUR 2.3 billion, of which international operations accounted for roughly 40 per cent. The Group employs an average of 8,200 people. Lemminkäinen Corporation’s share is quoted on NASDAQ OMX Nordic Exchange Helsinki. www.lemminkainen.com
(IN BRIEF) Eurex, on April 29, 2024, introduced a new Green Bond Basket within its…
(IN BRIEF) Last Friday, NMB Bank Plc celebrated the listing of its dual-currency sustainability bond,…
(IN BRIEF) CapMan Nordic Infrastructure II fund has reached its final closing at over €375…
(IN BRIEF) AstraZeneca and Daiichi Sankyo's Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated…
(IN BRIEF) AstraZeneca's Truqap, in combination with Faslodex, has received a positive recommendation from the…
(IN BRIEF) Ørsted, a global leader in renewable energy, is divesting its French onshore operations…